LINCOLN, Neb., Aug. 04, 2015 (GLOBE NEWSWIRE) -- National Research Corporation (NASDAQ:NRCIA) and (NASDAQ:NRCIB) today announced results for the second quarter of 2015.
- Net New Sales $6.8 million, up 64%
- Total Contract Value $107.8 million
- Revenue up 2% to $24.5 million
- Net Income of $4.1 million
Remarking on Company performance, Michael D. Hays, chief executive officer of National Research Corporation said, “Net new sales continue to exceed plan, which we expect will drive high single-digit top-line growth for the balance of 2015 and mid double-digit revenue growth for 2016.”
Revenue for the quarter ended June 30, 2015, was $24.5 million, compared to $24.0 million for the same quarter in 2014. Net income for both quarters ended June 30, 2015 and 2014, was $4.1 million. Diluted earnings per share remained at $0.10 for Class A shares and $0.57 for Class B shares for both quarters ended June 30, 2015 and 2014. Combined diluted earnings per share (a non-GAAP measure) stayed consistent at $0.16 for both quarters ended June 30, 2015 and 2014.
Regarding second quarter performance, Kevin Karas, chief financial officer of National Research Corporation, said, “We continued the trend of positive quarterly net new sales momentum and increase in contract value over the prior year, which will translate into higher revenue growth rates over the balance of this year. Investments to support our rapidly growing offerings continued in the quarter to sustain momentum in building total contract value.”
A listen-only simulcast of National Research Corporation’s 2015 second quarter conference call will be available online at http://edge.media-server.com/m/p/dd3s6ct8 on August 5, 2015, beginning at 11:00 a.m. Eastern time. The online replay will follow approximately one hour later and continue for 30 days.
For more than 34 years, National Research Corporation has been at the forefront of patient-centered care, helping healthcare providers measure and improve quality and services through analytics that offer a rich understanding of customers’ experiences, preferences, risks and behaviors across the healthcare continuum.
The information discussed within this release includes financial results and projections that are in accordance with accounting principles generally accepted in the United States (GAAP). In addition, certain non-GAAP financial measures have been provided that calculate combined earnings per share based on combined Class A and Class B shares and share equivalents outstanding, respectively. The non-GAAP measures should be read in conjunction with the corresponding GAAP measures and should be considered in addition to, and not as an alternative or substitute for, the measures prepared in accordance with GAAP. Please note that the Company’s non-GAAP measures may be different than those used by other companies. The additional non-GAAP financial information the Company presents should be considered in conjunction with, and not as a substitute for, the Company’s financial information presented in accordance with GAAP. The non-GAAP financial measures are provided in an effort to provide information that investors may deem relevant to evaluate results from the company's core business operations and to compare the company's performance with prior periods. The company uses both GAAP and these non-GAAP financial measures for evaluating comparable financial performance against prior periods.
This press release includes “forward-looking” statements related to the Company that can generally be identified as describing the Company’s future plans, objectives or goals. Such forward-looking statements are subject to risks and uncertainties that could cause actual results or outcomes to differ materially from those currently anticipated. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For further information about the factors that could affect the Company’s future results, please see the Company’s filings with the Securities and Exchange Commission.
| NATIONAL RESEARCH CORPORATION AND SUBSIDIARY | ||||||||||||||||
| Unaudited Condensed Consolidated Statements of Income | ||||||||||||||||
| (In thousands, except per share data) | ||||||||||||||||
| Three months ended | Six months ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2015 | 2014 | 2015 | 2014 | |||||||||||||
| Revenue | $ | 24,464 | $ | 24,001 | $ | 50,734 | $ | 50,031 | ||||||||
| Operating expenses: | ||||||||||||||||
| Direct expenses | 10,440 | 10,773 | 22,239 | 21,102 | ||||||||||||
| Selling, general and administrative | 6,636 | 5,984 | 14,263 | 12,349 | ||||||||||||
| Depreciation and amortization | 1,024 | 926 | 2,039 | 1,861 | ||||||||||||
| Total operating expenses | 18,100 | 17,683 | 38,541 | 35,312 | ||||||||||||
| Operating income | 6,364 | 6,318 | 12,193 | 14,719 | ||||||||||||
| Other income (expense): | ||||||||||||||||
| Interest income | 16 | 19 | 32 | 36 | ||||||||||||
| Interest expense | (57 | ) | (78 | ) | (120 | ) | (160 | ) | ||||||||
| Other, net | 2 | 7 | 2 | 14 | ||||||||||||
| Total other expense | (39 | ) | (52 | ) | (86 | ) | (110 | ) | ||||||||
| Income before income taxes | 6,325 | 6,266 | 12,107 | 14,609 | ||||||||||||
| Provision for income taxes | 2,261 | 2,215 | 4,563 | 5,104 | ||||||||||||
| Net income | $ | 4,064 | $ | 4,051 | $ | 7,544 | $ | 9,505 | ||||||||
| Earnings Per Share of Common Stock: | ||||||||||||||||
| Basic Earnings Per Share: | ||||||||||||||||
| Class A | $ | 0.10 | $ | 0.10 | $ | 0.18 | $ | 0.23 | ||||||||
| Class B | $ | 0.58 | $ | 0.58 | $ | 1.08 | $ | 1.37 | ||||||||
| Diluted Earnings Per Share: | ||||||||||||||||
| Class A | $ | 0.10 | $ | 0.10 | $ | 0.18 | $ | 0.22 | ||||||||
| Class B | $ | 0.57 | $ | 0.57 | $ | 1.07 | $ | 1.34 | ||||||||
| Weighted average shares and share equivalents outstanding | ||||||||||||||||
| Class A - basic | 20,790 | 20,771 | 20,791 | 20,757 | ||||||||||||
| Class B - basic | 3,478 | 3,474 | 3,478 | 3,472 | ||||||||||||
| Class A - diluted | 21,029 | 21,073 | 21,031 | 21,098 | ||||||||||||
| Class B - diluted | 3,522 | 3,539 | 3,523 | 3,540 | ||||||||||||
| NATIONAL RESEARCH CORPORATION AND SUBSIDIARY | ||||||||
| Unaudited Condensed Consolidated Balance Sheets | ||||||||
| (Dollars in thousands, except per share amounts and par value) | ||||||||
| Jun. 30, | Dec. 31, | |||||||
| 2015 | 2014 | |||||||
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 40,555 | $ | 40,042 | ||||
| Accounts receivable, net | 10,273 | 8,116 | ||||||
| Income taxes receivable | 759 | 1,100 | ||||||
| Other current assets | 4,184 | 3,930 | ||||||
| Total current assets | 55,771 | 53,188 | ||||||
| Property and equipment, net | 11,743 | 12,143 | ||||||
| Goodwill | 58,336 | 58,489 | ||||||
| Other, net | 5,198 | 5,690 | ||||||
| Total Assets | $ | 131,048 | $ | 129,510 | ||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable and accrued expenses | $ | 6,277 | $ | 6,028 | ||||
| Deferred revenue | 16,972 | 15,095 | ||||||
| Accrued compensation | 3,669 | 4,365 | ||||||
| Income taxes payable | - | 110 | ||||||
| Notes payable | 2,364 | 2,328 | ||||||
| Total Current Liabilities | 29,282 | 27,926 | ||||||
| Non-current liabilities | 12,071 | 13,836 | ||||||
| Total Liabilities | 41,353 | 41,762 | ||||||
| Shareholders’ Equity: | ||||||||
| Preferred stock, $0.01 par value, authorized 2,000,000 shares, none issued | -- | -- | ||||||
| Class A Common stock, $0.001 par value; authorized 60,000,000 shares, issued 25,538,056 in 2015 and 25,475,662 in 2014, outstanding 20,914,430 in 2015 and 20,894,286 in 2014 | 26 | 25 | ||||||
| Class B Common stock, $0.001 par value; authorized 80,000,000 shares, issued 4,262,287 in 2015 and 4,251,889 in 2014, outstanding 3,502,644 in 2015 and 3,494,865 in 2014 | 4 | 4 | ||||||
| Additional paid-in capital | 45,745 | 44,864 | ||||||
| Retained earnings | 76,197 | 73,686 | ||||||
| Accumulated other comprehensive loss | (1,542 | ) | (773 | ) | ||||
| Treasury stock | (30,735 | ) | (30,058 | ) | ||||
| Total shareholders’ equity | 89,695 | 87,748 | ||||||
| Total liabilities and shareholders’ equity | $ | 131,048 | $ | 129,510 | ||||
| NATIONAL RESEARCH CORPORATION AND SUBSIDIARY | ||||||||||||||||
| Unaudited Non-GAAP Combined Earnings Per Share Schedule | ||||||||||||||||
| (In thousands, except per share data) | ||||||||||||||||
| Three months ended | Six months ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2015 | 2014 | 2015 | 2014 | |||||||||||||
| Combined Earnings Per Share | ||||||||||||||||
| Basic Earnings Per Share | $ | 0.17 | $ | 0.17 | $ | 0.31 | $ | 0.39 | ||||||||
| Diluted Earnings Per Share | $ | 0.16 | $ | 0.16 | $ | 0.31 | $ | 0.39 | ||||||||
| Combined weighted average shares and share equivalents outstanding | ||||||||||||||||
| Combined - Basic | 24,268 | 24,245 | 24,269 | 24,228 | ||||||||||||
| Combined - Diluted | 24,551 | 24,613 | 24,554 | 24,638 | ||||||||||||